Fujifilm starts production of Avigan for the treatment of Ebola

21 October 2014

Japan’s Fujifilm says it has decided to start production of the anti-influenza drug Avigan (favipiravir) 200mg tablets in preparation for administration to a larger number of patients with Ebola virus disease (EVD) overseas to counter the spread of EVD. The drug was approved in Japan as an anti-influenza treatment in March 2014.

Avigan tablets were developed by Fujifilm group company Toyama Chemical as an anti-influenza drug. Some research papers report that Avigan also shows efficacy against the Ebola virus in animal testing with mice, and Avigan has already been administered as an emergency treatment to several EVD patients evacuated from West Africa to Europe. Fujifilm provided Avigan to these patients in response to requests from governments and medical organizations treating the evacuated patients following discussions with the Japanese government.

France and Guinea to conduct clinical trials

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK